Chinoy Roshni F
Department of Pathology, Tata Memorial Hospital, Parel, Mumbai 400 012.
Indian J Pathol Microbiol. 2003 Apr;46(2):153-64.
Many breast carcinomas probably arise in a multi-step fashion through a series of intermediate lesions viz. ductal hyperplasia to atypical ductal hyperplasias to ductal carcinoma in situ (DCIS), and thence to invasive ductal cancer, each of which has a greater probability of becoming malignant than the one that preceded it. These precursor lesions have differing risk implications, hence treatment decisions vary with the risk. The heterogeneous lesions that come under the heading of hyperplasias and DCIS can cause problems for the histopathologists unless there is a conceptual understanding of the disease process. Since the surgical pathology report is the final word in cases of DCIS/LCIS, the pathologist becomes a vital partner in the decision making team.
许多乳腺癌可能通过一系列中间病变以多步骤方式发生，即从导管增生到非典型导管增生，再到导管原位癌（DCIS），进而发展为浸润性导管癌，每一步病变发展为恶性的可能性都比前一步更高。这些前驱病变具有不同的风险意义，因此治疗决策因风险而异。增生和DCIS范畴内的异质性病变会给组织病理学家带来问题，除非对疾病过程有概念性的理解。由于手术病理报告在DCIS/LCIS病例中具有最终决定权，病理学家成为决策团队中至关重要的一员。
